Decibel Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Decibel Therapeutics's estimated annual revenue is currently $9.3M per year.
- Decibel Therapeutics received $55.0M in venture funding in June 2018.
- Decibel Therapeutics's estimated revenue per employee is $155,000
- Decibel Therapeutics's total funding is $87.3M.
- Decibel Therapeutics has 60 Employees.
- Decibel Therapeutics grew their employee count by -33% last year.
- Decibel Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Decibel Therapeutics?
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. Hearing loss is the most prevalent form of sensory impairment. It is estimated that 50 million people in the U.S., and 360 million people worldwide, suffer from some type of hearing loss. Hearing disorders affect people of all ages and can have a profound impact on quality of life. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. Founded by the world's preeminent experts in inner ear biology and hearing disorders, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and SR One and is headquartered in Boston, Mass. For more information and to browse career opportunities at Decibel Therapeutics, please visit decibeltx.com.keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics
Number of Employees
Employee Growth %
|John Keilty||Chief Data Sciences Officer||Email Available|
|Michael Su||Chief Scientific Officer||Email Available|
|Fuxin Shi||Director||Email Available|
|CHRISTOPHER HREN||Senior Director, Corporate Development||Email Available|
|Jason Kropp||Associate Director, Cmc Operations||Email Available|
|Elaine Cope||Senior Director, Facilities||Email Available|
|Ada Silos-santiago||VP Pharmacology|
|William Oemler||Senior Manager, Software Engineering|
|Daniel Rosan||Vice President Corporate Development||Email Available|
|Adam Palermo||Senior Director And Head Of Genomics And Computational Biology||Email Available|
Decibel Therapeutics News
Frequency Therapeutics is developing a hearing loss drug that taps into the ... Another Boston firm, Decibel Therapeutics, is developing small ...
The letter was written together by Ovid Therapeutics CEO and ... Acorda Therapeutics CEO Ron Cohen, Decibel Therapeutics CEO Steven ...
BOSTON--(BUSINESS WIRE)-- Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss ...
Decibel Therapeutics Funding
|2015-10-16||$52.0M||A||Third Rock Ventures LLC||Article|
Decibel Therapeutics Executive Hires
|2016-07-14||Steven H Holtzman||President & CEO||Article|
|2016-09-08||Michael Su||Chief Scientific Officer||Article|
|2017-01-19||John Keilty||Chief Data Sciences Officer||Article|
|2019-02-06||Peter Weber||Chief Medical Officer||Article|